ABSTRACT
Obesity is an increasingly prevalent problem with many associated health risks. Obese patients may present with liver diseases directly attributable to their obesity, such as nonalcoholic steatohepatitis (NASH). However, many such individuals are prescribed various potentially hepatotoxic medications for obesity itself, as well as for the complications of obesity. Clinically, it may be difficult to distinguish the two. Furthermore, many of these medications are in common use, and some are not commonly recognized as potentially injurious to the liver. While some medications have predictable hepatotoxicity, many more have associated idiosyncratic reactions. We review the literature and case-reports of hepatotoxicity associated with four categories of medications: those used primarily in the treatment of obesity, those used in the treatment of diabetes mellitus, those used in the treatment of hyperlipidemia, and those used in the treatment of hypertension. For each class, we present the described epidemiology, clinical presentation, pathology, and prognosis.
KEYWORDS
Obesity - diabetes - hypertension - hyperlipidemia - drug-induced hepatotoxicity
REFERENCES
-
1
Kuczmarski R J.
Prevalence of overweight and weight gain in the United States.
Am J Clin Nutr.
1992;
55
495S-502S
-
2
Kuczmarski R J, Flegal K M, Campbell S M, Johnson C L.
Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991.
JAMA.
1994;
272
205-211
-
3
Ford E S, Mokdad A H, Giles W H.
Trends in waist circumference among U.S. adults.
Obes Res.
2003;
11
1223-1231
-
4
McIntyre A M.
Burden of illness review of obesity: are the true costs realised?.
J R Soc Health.
1998;
118
76-84
-
5
Lau D.
Call for action: preventing and managing the expansive and expensive obesity epidemic.
CMAJ.
1999;
160
503-506
-
6
James O F, Day C P.
Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance.
J Hepatol.
1998;
29
495-501
-
7
Byron D, Minuk G Y.
Profile of an urban hospital-based practice.
Hepatology.
1996;
24
813-815
-
8
Skelly M M, James P D, Ryder S D.
Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.
J Hepatol.
2001;
35
195-199
-
9
Zimmerman H J.
Drug-induced liver disease.
Clin Liver Dis.
2000;
4
73-96
-
10
Lee W M.
Drug-induced hepatotoxicity.
N Engl J Med.
1995;
333
1118-1127
-
11
Haddock C K, Poston W SC, Dill P L, Foreyt J P, Ericsson M.
Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.
Int J Obes Relat Metab Disord.
2002;
26
262-273
-
12 Meridia [package insert]. .Chicago, IL; Abbott 2000
-
13
Golik A, Rubio A, Weintraub M, Byrne L.
Elevated serum liver enzymes in obesity: a dilemma during clinical trials.
Int J Obes.
1991;
15
797-801
-
14
Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum M L.
Sibutramine in weight control: a dose-ranging, efficacy study.
Clin Pharmacol Ther.
1991;
50
330-337
-
15
Montero J L, Muntane J, Fraga E et al..
Orlistat associated subacute hepatic failure.
J Hepatol.
2001;
34
173
-
16
Lau G, Chan C L.
Massive hepatocellular necrosis: was it caused by Orlistat?.
Med Sci Law.
2002;
42
309-312
-
17
Kim D H, Lee E H, Hwang J C et al..
A case of acute cholestatic hepatitis associated with Orlistat [in Korean].
Taehan Kan Hakhoe Chi.
2002;
8
317-320
-
18
Barbare J C, Imbert A, Benkirane A.
Hepatotoxicity of medications.
Presse Med.
2001;
30
673-676
-
19
Christidis C, Mal F, Gayet B, Guettier C.
Is xenical hepatotoxic?.
[in French] Gastroenterol Clin Biol.
2000;
24
374
-
20
Sanyal A J, Campbell-Sargent C, Mirshahi F et al..
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
Gastroenterology.
2001;
120
1183-1192
-
21
Marchesini G, Bugianesi E, Forlani G et al..
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.
Hepatology.
2003;
37
917-923
-
22
Asherov J, Mimouni M, Varsano I, Lubin E, Laron Z.
Hepatomegaly due to self-induced hyperinsulinism.
Arch Dis Child.
1979;
54
148-149
-
23
Tawata M, Ikeda M, Kodama Y, Aida K, Onaya T.
A type 2 diabetic patient with liver dysfunction due to human insulin.
Diabetes Res Clin Pract.
2000;
49
17-21
-
24
Wanless I R, Bargman J M, Oreopoulos D G, Vas S I.
Insulin and steatonecrosis: are they related?.
Mod Pathol.
1989;
2
69-74
-
25
Kallio T, Nevalainen P I, Lahtela J T, Mustonen J, Pasternack A.
Hepatic subcapsular steatosis in diabetic CAPD patients treated with intraperitoneal insuli. Description of a typical patternn.
Acta Radiol.
2001;
42
323-325
-
26
Burrows C J, Jones A W.
Hepatic subcapsular steatosis in a patient with insulin-dependent diabetes receiving dialysis.
J Clin Pathol.
1994;
47
274-275
-
27
Grove A, Vyberg B, Vyberg M.
Focal fatty change of the liver. A review and a case associated with continuous ambulatory peritoneal dialysis.
Virchows Arch A Pathol Anat Histopathol.
1991;
419
69-75
-
28
Khalili K, Lan F P, Hanbidge A E et al..
Hepatic subcapsular steatosis in response to intraperitoneal insulin delivery: CT findings and prevalence.
AJR Am J Roentgenol.
2003;
180
1601-1604
-
29
Schneider H L, Hornbach K D, Kniaz J L, Efrusy M E.
Chlorpropamide hepatotoxicity: report of a case and review of the literature.
Am J Gastroenterol.
1984;
79
721-724
-
30
Baig N A, Herrine S K, Rubin R.
Liver disease and diabetes mellitus.
Clin Lab Med.
2001;
21
193-207
-
31
Van Thiel D H, Belle R D, Mellow M, Widerlite L, Philipps E.
Tolazamide hepatotoxicity. A case report.
Gastroenterology.
1974;
67
506-510
-
32
Rigberg L A, Robinson M J, Espiritu C R.
Chlorpropamide-induced granulomas. A probable hypersensitivity reaction in liver and bone marrow.
JAMA.
1976;
235
409-410
-
33
van Basten J P, van Hoek B, Zeijen R, Stockbrugger R.
Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature.
Neth J Med.
1992;
40
305-307
-
34
Petrogiannopoulos C, Zacharof A.
Glibenclamide and liver disease.
Diabetes Care.
1997;
20
1215
-
35
Saw D, Pitman E, Maung M et al..
Granulomatous hepatitis associated with glyburide.
Dig Dis Sci.
1996;
41
322-325
-
36
Goodman R C, Dean P J, Radparvar A, Kitabchi A E.
Glyburide-induced hepatitis.
Ann Intern Med.
1987;
106
837-839
-
37
Nakao N L, Gelb A M, Stenger R J, Siegel J H.
A case of chronic liver disease due to tolazamide.
Gastroenterology.
1985;
89
192-195
-
38
Chan K A, Truman A, Gurwitz J H et al..
A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.
Arch Intern Med.
2003;
163
728-734
-
39
Babich M M, Pike I, Shiffman M L.
Metformin-induced acute hepatitis.
Am J Med.
1998;
104
490-492
-
40
Deutsch M, Kountouras D, Dourakis S P.
Metformin hepatotoxicity.
Ann Intern Med.
2004;
140
W25
-
41
Nammour F E, Fayad N F, Peikin S R.
Metformin-induced cholestatic hepatitis.
Endocr Pract.
2003;
9
307-309
-
42
Chiasson J L, Josse R G, Hunt J A et al..
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Ann Intern Med.
1994;
121
928-935
-
43
Madonia S, Pietrosi G, Pagliaro L.
Acarbose-induced liver injury in an anti-hepatitis C virus positive patient.
Dig Liver Dis.
2001;
33
615-616
-
44
Andrade R J, Lucena M, Vega J L et al..
Acarbose-associated hepatotoxicity.
Diabetes Care.
1998;
21
2029-2030
-
45
Diaz-Gutierrez F L, Ladero J M, Diaz-Rubio M.
Acarbose-induced acute hepatitis.
Am J Gastroenterol.
1998;
93
481
-
46
Kawakami S, Arima T, Harada K et al..
Hepatic necrosis with cholestasis induced by long-term voglibose administration.
Intern Med.
2001;
40
484-488
-
47
Tomita K, Azuma T, Kitamura N et al..
Pioglitzone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met.
Gastroenterology.
2004;
126
873-895
-
48
Neuschwander-Tetri B A, Brunt E M, Wehmeier K R et al..
Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
J Hepatol.
2003;
38
434-440
-
49
Caldwell S H, Hespenheide E E, Redick J A et al..
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Am J Gastroenterol.
2001;
96
519-525
-
50
Galli A, Crabb D W, Ceni E et al..
Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.
Gastroenterology.
2002;
122
1924-1940
-
51
Watkins P B, Whitcomb R W.
Hepatic dysfunction associated with troglitazone.
N Engl J Med.
1998;
338
916-917
-
52
Jick S S, Stender M, Myers M W.
Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents.
Diabetes Care.
1999;
22
2067-2071
-
53
Henney J E.
From the Food and Drug Administration: withdrawal of troglitazone and cisapride.
JAMA.
2000;
283
2228
-
54
Wise J.
Diabetes drug withdrawn after reports of hepatic events.
BMJ.
1997;
315
1564
-
55
Neuschwander-Tetri B A, Isley W L, Oki J C et al..
Troglitazone-induced hepatic failure leading to liver transplantation. A case report.
Ann Intern Med.
1998;
129
38-41
-
56
Vella A, de Groen P C, Dinneen S F.
Fatal hepatotoxicity associated with troglitazone.
Ann Intern Med.
1998;
129
1080
-
57
Herrine S K, Choudhary C.
Severe hepatotoxicity associated with troglitazone.
Ann Intern Med.
1999;
130
163-164
-
58
Menon K VN, Angulo P, Lindor K D.
Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Am J Gastroenterol.
2001;
96
1631-1634
-
59
Graham D J, Green L, Senior J R, Nourjah P.
Troglitazone-induced liver failure: a case study.
Am J Med.
2003;
114
299-306
-
60
Maeda K.
Hepatocellular injury in a patient receiving pioglitazone.
Ann Intern Med.
2001;
135
306
-
61
May L D, Lefkowitch J H, Kram M T, Rubin D E.
Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy.
Ann Intern Med.
2002;
136
449-452
-
62
Chase M P, Yarze J C.
Pioglitazone-associated fulminant hepatic failure.
Am J Gastroenterol.
2002;
97
502
-
63
Al-Salman J, Arjomand H, Kemp D G, Mittal M.
Hepatocellular injury in a patient receiving rosiglitazone. A case report.
Ann Intern Med.
2000;
132
121-124
-
64
Dhawan M, Agrawal R, Ravi J et al..
Rosiglitazone-induced granulomatous hepatitis.
J Clin Gastroenterol.
2002;
34
582-584
-
65
Gouda H E, Khan A, Schwartz J, Cohen R I.
Liver failure in a patient treated with long-term rosiglitazone therapy.
Am J Med.
2001;
111
584-585
-
66
Forman L M, Simmons D A, Diamond R H.
Hepatic failure in a patient taking rosiglitazone.
Ann Intern Med.
2000;
132
118-121
-
67
Nagasaka S, Abe T, Kawakami A et al..
Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Diabet Med.
2002;
19
347-348
-
68
Lenhard M J, Funk W B.
Failure to develop hepatic injury from rosiglitazone in a patient with a history of troglitazone-induced hepatitis.
Diabetes Care.
2001;
24
168-169
-
69
Tolman K G.
Defining patient risks from expanded preventive therapies.
Am J Cardiol.
2000;
85
15E-19E
-
70
Chitturi S, George J.
Hepatotoxicity of commonly used drugs.
Semin Liver Dis.
2002;
22
169-183
-
71
Tolman K G.
The liver and lovastatin.
Am J Cardiol.
2002;
89
1374-1380
-
72
Migneco G, Mascarella A, Ferla A L, Attianese R.
Clofibrate hepatitis. A case report.
Minerva Med.
1986;
77
799-800
-
73
Tobert J A.
Efficacy and long-term adverse effect pattern of lovastatin.
Am J Cardiol.
1988;
62
28J-34J
-
74
Zimmerman H J, Ishak K G.
General aspects of drug-induced liver disease.
Gastroenterol Clin North Am.
1995;
24
739-757
-
75
Downs J R, Clearfield M, Weis S et al..
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
JAMA.
1998;
279
1615-1622
-
76
Pfeffer M A, Keech A, Sacks F M et al..
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
Circulation.
2002;
105
2341-2346
-
77
Dujovne C A, Chremos A N, Pool J L et al..
Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.
Am J Med.
1991;
91
25S-30S
-
78
Farmer J A, Torre-Amione G.
Comparative tolerability of the HMG-CoA reductase inhibitors.
Drug Saf.
2000;
23
197-213
-
79
Black D M.
A general assessment of the safety of HMG CoA reductase inhibitors (statins).
Curr Atheroscler Rep.
2002;
4
34-41
-
80
Chalasani N, Aljadhey H, Kesterson J, Murray M D, Hall S D.
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
Gastroenterology.
2004;
126
1287-1292
-
81
Russo M W, Jacobson I M.
How to use statins in patients with chronic liver disease.
Cleve Clin J Med.
2004;
71
58-62
-
82
Hartleb M, Rymarczyk G, Januszewski K.
Acute cholestatic hepatitis associated with pravastatin.
Am J Gastroenterol.
1999;
94
1388-1390
-
83
Geddes J A.
Cholestatic jaundice associated with lovastatin (mevacor) therapy.
CMAJ.
1990;
143
13-14
-
84
McKenney J M, Proctor J D, Harris S, Chinchili V M.
A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients.
JAMA.
1994;
271
672-677
-
85
Furhoff A K.
Adverse reactions with methyldopa-a decade's reports.
Acta Med Scand.
1978;
203
425-428
-
86
Shalev O, Mosseri M, Ariel I, Stalnikowicz R.
Methyldopa-induced immune hemolytic anemia and chronic active hepatitis.
Arch Intern Med.
1983;
143
592-593
-
87
Lahoti S, Lee W M.
Hepatotoxicity of anticholesterol, cardiovascular, and endocrine drugs and hormonal agents.
Gastroenterol Clin North Am.
1995;
24
907-922
-
88
Zimmerman H J.
Hepatotoxicity.
Dis Mon.
1993;
39
675-787
-
89
Thomas L A, Cardwell M S.
Acute reactive hepatitis in pregnancy induced by alpha-methyldopa.
Obstet Gynecol.
1997;
90
658-659
-
90
Mirada Canals A, Monteagudo Jimenez M, Sole Villa J, Rodriguez Moreno C.
Methyldopa-induced granulomatous hepatitis.
DICP.
1991;
25
1269-1270
-
91
Garovic V C.
Hypertension in pregnancy: diagnosis and treatment.
Mayo Clin Proc.
2000;
75
1071-1076
-
92
Michelson E.
Labetalol hepatotoxicity.
Ann Intern Med.
1991;
114
341
-
93
Clark J A, Zimmerman H J, Tanner L A.
Labetalol hepatotoxicity.
Ann Intern Med.
1990;
113
210-213
-
94
Stravitz R T, Sanyal A J.
Drug-induced steatohepatitis.
Clin Liver Dis.
2003;
7
435-451
-
95
Faust G.
The tolerability of nilvadipine compared to nifedipine in patients with essential hypertension.
J Cardiovasc Pharmacol.
1992;
20
S56-S61
-
96
Basile C, Mascia E.
Dihydropyridine calcium channel blockers: a rare and reversible cause of hepatotoxicity with cholestasis in a CAPD patient.
Nephrol Dial Transplant.
1999;
14
2776-2777
-
97
Lafuente N G.
Calcium channel blockers and hepatotoxicity.
Am J Gastroenterol.
2000;
95
2145
-
98
Nygaard B, Strandgaard S.
Marked hepatotoxicity associated with losartan treatment.
Blood Press.
1996;
5
190-191
-
99
Tabak F, Mert A, Ozaras R et al..
Losartan-induced hepatic injury.
J Clin Gastroenterol.
2002;
34
585-586
-
100
Gonzalez-Jimenez D, Varela J M, Calderon E, Galindo J, Gonzalez de la Puente M A.
Candesartan and acute liver injury.
Eur J Clin Pharmacol.
2000;
56
769-770
-
101
Kiykim A, Altintas E, Sezgin O et al..
Valsartan-induced hepatotoxicity in a HBs-Ag-Positive patient.
Am J Gastroenterol.
2003;
98
507
-
102
Basile G, Villari D, Gangemi S, Nicita-Mauro V.
Candesartan cilexetil-induced severe hepatotoxicity.
J Clin Gastroenterol.
2003;
36
273-275
-
103
Nunes A C, Amaro P, Macas F et al..
Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report.
Eur J Gastroenterol Hepatol.
2001;
13
279-282
-
104
Schattner A, Kozak N, Friedman J.
Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature.
Am J Med Sci.
2001;
322
236-240
-
105
Bas V, Erkan T, Caliskan S et al..
Toxic hepatitis due to enalapril in childhood.
Pediatr Int.
2003;
45
755-757
-
106
Macias F M, Campos F R, Salguero T P, Soria P T, Carrasco F G, Martin J M.
Ductopenic hepatitis related to Enalapril.
J Hepatol.
2003;
39
1091-1092
-
107
Droste H T, de Vries R A.
Chronic hepatitis caused by lisinopril.
Neth J Med.
1995;
46
95-98
-
108
Jeserich M, Ihling C, Allgaier H P, Berg P A, Heilmann C.
Acute liver failure due to enalapril.
Herz.
2000;
25
689-693
-
109
Yeung E, Wong F S, Wanless I R et al..
Ramipril-associated hepatotoxicity.
Arch Pathol Lab Med.
2003;
127
1493-1497
-
110
Pariente E A, Pessayre D, Bernuau J, Degott C, Benhamou J P.
Dihydralazine hepatitis: report of a case and review of the literature.
Digestion.
1983;
27
47-52
-
111
Tameda Y, Hamada M, Takase K, Nakano T, Kosaka Y.
Fulminant hepatic failure caused by ecarazine hydrochloride (a hydralazine derivative).
Hepatology.
1996;
23
465-470
-
112
Rice D, Burdick C O.
Granulomatous hepatitis from hydralazine therapy.
Arch Intern Med.
1983;
143
1077
-
113 Meridia (R). Physicians' Desk Reference, 37th ed. New York; Thomson 2000: 475-480
-
114
Mehta H, Murray B, LoIudice T A.
Hepatic dysfunction due to intravenous abuse of methylphenidate hydrochloride.
J Clin Gastroenterol.
1984;
6
149-151
-
115
Cai Q, Benson M A, Talbot T J et al..
Acute hepatitis due to fluoxetine therapy.
Mayo Clin Proc.
1999;
74
692-694
-
116
Friedenberg F K, Rothstein K D.
Hepatitis secondary to fluoxetine treatment.
Am J Psychiatry.
1996;
153
580
-
117
Wernicke J F.
The side effect profile and safety of fluoxetine.
J Clin Psychiatry.
1985;
46
59-67
-
118 Anonymous. .FDA Dear Healthcare Professional Letter 2001
-
119
Brown G, Zoidis J, Spring M.
Hepatic damage during chlorpropamide therapy.
JAMA.
1959;
170
2085-2088
-
120
Reichel J, Goldberg S B, Ellenberg M.
Intrahepatic cholestasis following administration of chlorpropamide: report of a case with electron microscopic observations.
Am J Med.
1960;
28
654-660
-
121
Meadow P, Tullio C J.
Glyburide-induced hepatitis.
Clin Pharm.
1989;
8
470
-
122
Ananth J V, Ban T A, Lehmann H E.
Tolbutamide jaundice associated with multiple drug therapy.
Can Med Assoc J.
1970;
103
1194
-
123
Gregory D H, Zaki G F, Sarcos G R et al..
Chronic cholestasis following prolonged tolbutamide administration associated with destructive cholangitis and cholangiolitis.
Arch Pathol.
1967;
84
194-201
-
124
Bridges M E, Pittman F E.
Tolazamide-induced cholestasis.
South Med J.
1980;
73
1072-1074
-
125
LoIudice T A, Lang J A.
Tolazamide-induced hepatic dysfunction.
Am J Gastroenterol.
1978;
69
81-83
-
126
Puppala A R, Steinheber F U.
Fulminant hepatic failure associated with methyldopa.
Am J Gastroenterol.
1977;
68
578-581
-
127
Rehman O U, Keith T A, Gall E A.
Methyldopa-induced submassive hepatic necrosis.
JAMA.
1973;
224
1390-1392
-
128
Hagmeyer K O, Stein J.
Hepatotoxicity associated with carvedilol.
Ann Pharmacother.
2001;
35
1364-1366
Keith D LindorM.D.
Mayo Clinic-W19A, 200 First Street, SW
Rochester, MN 55905
Email: lindor.keith@mayo.edu
